Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)
Status:
Withdrawn
Trial end date:
2017-03-22
Target enrollment:
Participant gender:
Summary
The specific aim of this trial is to determine whether initiating moderate- or high-intensity
atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation
and lowers average Epogen utilization. Statin naive patients on maintenance HD will be
started on 20mg atorvastatin daily for weeks and then titrated up to 40mg atorvastatin daily
for an additional 12 weeks. Patient's inflammatory markers (ferritin, CRP) and weekly Epogen
usage will be monitored.